Breast cancer

“Synthetic lethality” is where genetic mutations that normally don’t harm a cell become deadly when paired up. Now, scientists have found a way to use this to selectively kill off cancer caused by genetic mutations, without harming healthy cells.

University of Pennsylvania scientists have demonstrated how a glowing dye can be used to light up cancer cells in tumors and the lymph nodes of dogs, which they say offers hope for improved surgical outcomes in humans.

Adding to the burgeoning potential of ultrasound to treat cancer is a new study that combines the technology with microbubbles, which can be blasted apart like a “targeted warhead” to destroy the majority of tumor cells in breast cancer models.

Part of what makes cancer so deadly is its ability to rapidly spread to other parts of the body. Now, researchers at Tulane University have identified a pair of genes that helps triple negative breast cancer spread – and found how to switch them off.

Scientists at Harvard have come up with a new way to supercharge immune cells that are one of our key defenses against cancerous cells, equipping them with a type of “backpack” that slows tumor growth in mice with an aggressive form of breast cancer.

The FDA has approved two new kinds of breast cancer treatments, one targeting HER2-positive cancers and a second for metastatic triple-negative breast cancer. The approval for both treatments was expedited due to the novel coronavirus pandemic.

A new study has shown that an experimental class of cancer drugs has wider potential than previously thought. Researchers have found a new type of BET inhibitor that, in mouse tests, can target solid tumors more effectively and safely than others.

A new AI system is proving more effective at detecting breast cancer in mammograms than trained radiologists. The software, developed by researchers from Google, is not designed to replace humans but instead improve current diagnostic processes.

A new study claims a novel blood test can identify breast cancer years before clinical signs of the disease appear. The blood test is only in its preliminary stages of development, however, some scientists are skeptical of the researchers’ claims.

In preclinical tests, scientists at Wistar Institute have developed a molecule that disrupts a protein complex vital to cancer cell survival.

A study suggests the drugs used to initially treat breast cancer may be triggering some cancer cells to enter a dormant state.

A new blood test has been developed that promises to be able to effectively track the progression of breast cancer at its earliest stages. It is suggested the blood test could track the efficacy of drug therapies better than current imaging techniques and prevent unnecessary surgical procedures.